Capital Fund Management S.A. Has $18.85 Million Stock Position in Hologic, Inc. $HOLX

Key Points

• Capital Fund Management S.A. increased its holdings in Hologic, Inc. by 92.7%, owning 305,176 shares valued at approximately $18.85 million after purchasing an additional 146,800 shares in Q1.
• Hologic reported earnings of $1.08 per share, beating estimates of $1.05, with revenues of $1.02 billion for the quarter, reflecting a year-over-year increase of 1.2%.
• Analysts have varied opinions on Hologic, with one Strong Buy, eight Buy, and eight Hold ratings, leading to a consensus price target of $78.00.

Capital Fund Management S.A. raised its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 92.7% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 305,176 shares of the medical equipment provider's stock after buying an additional 146,800 shares during the period. Capital Fund Management S.A. owned approximately 0.14% of Hologic worth $18,851,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of HOLX. Victory Capital Management Inc. increased its stake in Hologic by 34.4% in the 1st quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider's stock worth $408,283,000 after purchasing an additional 1,692,177 shares in the last quarter. Nuance Investments LLC boosted its holdings in shares of Hologic by 623.7% in the first quarter. Nuance Investments LLC now owns 1,081,333 shares of the medical equipment provider's stock worth $66,794,000 after buying an additional 931,920 shares during the period. Redwood Wealth Management Group LLC acquired a new position in shares of Hologic in the first quarter worth about $3,534,000. Invesco Ltd. increased its position in shares of Hologic by 18.8% in the first quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider's stock worth $298,655,000 after acquiring an additional 764,573 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in shares of Hologic by 26.9% during the fourth quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider's stock valued at $226,898,000 after acquiring an additional 668,086 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently issued reports on HOLX. Mizuho set a $75.00 target price on Hologic in a report on Thursday, July 31st. Raymond James Financial reissued an "outperform" rating and issued a $71.00 price target (down previously from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Needham & Company LLC reissued a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. Wall Street Zen upgraded shares of Hologic from a "hold" rating to a "buy" rating in a research note on Friday. Finally, Citigroup upgraded Hologic from a "neutral" rating to a "buy" rating and increased their target price for the company from $60.00 to $80.00 in a research note on Wednesday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $78.00.

Hologic Stock Performance

Shares of NASDAQ HOLX traded up $1.09 during trading hours on Friday, reaching $68.26. The stock had a trading volume of 1,545,907 shares, compared to its average volume of 1,851,908. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.39. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The business's fifty day moving average is $65.90 and its two-hundred day moving average is $62.42. The company has a market cap of $15.18 billion, a price-to-earnings ratio of 28.32, a PEG ratio of 2.48 and a beta of 0.49.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.03. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business's revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, research analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.